REPLIGEN CORP (RGEN): what the price assumes

In the published model solve dated 2026-Q2, anchored at $158.72, REPLIGEN CORP (RGEN) is priced for today's economics sustained for ~22.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/RGEN

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Solve inputs: computed at a 11.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.9 years.

Reconcile: at the x-ray's 9.3% required return this reads ~17.3 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.

Per-Model Detail (n=14)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

At $131.96, Repligen is priced for a bioprocessing recovery the current 8.5 percent operating margin does not yet reflect. The price implies a very long runway of margin expansion, so the static valuation methods, which capitalize today's depressed earnings, all say richly valued.

The inflection is underway. First-quarter 2026 revenue rose 15 percent to $194 million, with 11 percent organic growth, adjusted EPS of $0.48 beat by more than a quarter, and China revenue nearly doubled as the post-pandemic destocking that hurt the industry fades.

The asset the static models cannot see is the consumables franchise: filtration, chromatography, and analytics products embedded in customers' drug-manufacturing lines. That recurring, sticky position re-rates the whole company if biologics spending keeps recovering, which is the entire bet.

Bull Case

Traditional valuation models miss what Repligen actually owns. On the asset and earnings frames, the stock looks absurdly expensive: the excess-return models land near $5 to $10 and earnings-power value near $14.57, a fraction of the $131.96 price, because Repligen's trailing operating margin is a depressed 8.5 percent. But those margins are cyclically suppressed by the bioprocessing destocking that gripped the whole industry after the pandemic, and the income statement understates the franchise. Repligen sells filtration, chromatography, process-analytics, and proteins products that are designed into customers' biologic-drug manufacturing processes (FY2025 10-K, accession 0001193125-26-076528). Once a tool is qualified into a regulated drug-production line, it is costly and slow to replace, so the revenue is recurring and sticky in a way a snapshot of trailing margin cannot capture.

The recovery is no longer a forecast; it is in the numbers. First-quarter 2026 revenue rose 15 percent year over year to $194 million, with 11 percent organic growth, and adjusted EPS of $0.48 beat the $0.38 consensus by more than 26 percent. GAAP EPS rose 50 percent. The rebound was broad, led by Process Analytics and Chromatography, with Asia-Pacific surging as China revenue nearly doubled. Destocking running off and order trends improving is exactly the signature of a consumables business returning to its structural growth rate, which management and analysts peg in the mid-teens over the medium term.

Management is sharpening the business at the same time. Repligen divested its lower-margin Polymem filtration operation in March 2026 to focus on higher-margin core franchises, and launched a Transformation Office to drive operational efficiency and margin expansion (the strategy of broadening its bioprocessing scope and customer base is laid out in the FY2025 10-K, accession 0001193125-26-076528). The company carries net cash of roughly $238 million, giving it flexibility to invest and acquire. The methods that fit a recovering growth franchise support the price: the DCF exit-multiple lands near $144.70 and the discounted-future-market-cap near $134.61, both around the price. Repligen raised full-year adjusted EPS guidance to $1.97 to $2.05, and analysts carry a Buy consensus with a median target near $180. The bull case is that the static methods are mispricing a high-quality, recurring-revenue bioprocessing leader at the bottom of its cycle.

Bear Case

Frame the bear case around the valuation methods, because the disagreement is extreme and the conservative methods are the more honest read of what Repligen earns today. Nearly every static frame screams expensive: residual income lands near $4.14, the two-stage excess-return near $5.65, earnings-power value near $14.57, the Graham number near $27.58, and the blended X-ray central estimate near $32.21, all a fraction of the $131.96 price (June 28, 2026). Only the growth-DCF and forward-market-cap methods, which extrapolate a full recovery and years of compounding, reach the price. When a stock trades at four to thirty times what the grounded methods support and rests on a single optimistic lens, the price is a bet on a future that has to arrive exactly as hoped, and the forward fair-value estimate here carries a low reliability flag for that reason.

The specific risk is that bioprocessing demand is volatile and the recovery may be slower or shallower than the price assumes. Repligen's own filings note that significant unanticipated changes in demand or unexpected quality failures could materially impact inventory value and reported operating results (FY2025 10-K, accession 0001193125-26-076528). The industry just lived through a brutal destocking cycle that crushed margins from their pandemic peak; nothing guarantees the rebound is linear. China nearly doubling is encouraging but also concentrates the recovery in a geography exposed to its own policy and reimbursement risks. If biologics capital spending stalls or customers work down inventory again, the 8.5 percent margin stays depressed and the duration the price assumes stretches further.

Third, the price embeds an implausibly long runway. The implied duration runs past 22 years, meaning the market is underwriting more than two decades of compounding to justify the current level. Repligen has grown historically through acquisitions, which carry goodwill and integration risk and complicate the organic growth picture. The current operating margin near 8.5 percent must climb substantially and the company must sustain mid-teens growth for a very long time for the math to close. At a price this far above the conservative methods, any disappointment, a guidance cut, a slower China, a quality issue, or simply a multiple that compresses as rates or sentiment shift, sends the stock toward the $30 to $50 range the grounded methods support rather than the $180 analyst target.

Valuation

Repligen is a duration bet on a bioprocessing recovery, and the methods make the wager unmistakable. At $131.96 the price is held up only by the growth-DCF family, while the asset, earnings-power, and peer-multiple methods all say richly valued, with an implied duration past 22 years and an elevated composite. The current operating margin near 8.5 percent is cyclically depressed, which is why the methods that capitalize current earnings land so far below the price.

The spread is enormous. On the low end, residual income lands near $4.14, the two-stage excess-return near $5.65, the simple excess-return near $9.81, and earnings-power value near $14.57, all reflecting depressed current returns on a capital base inflated by past acquisitions. In the middle, the Graham number lands near $27.58 and EV/EBITDA relative near $21.95. Only the forward lenses reach the price: the DCF exit-multiple near $144.70 and the discounted-future-market-cap near $134.61. The blended X-ray central estimate sits near $32.21.

The honest framing is that Repligen cannot be valued off trailing fundamentals because its earnings are mid-cycle-depressed; the static methods are correctly reporting that the current cash flow does not justify the price, while the forward methods bet on the recovery. The numbers to weigh are the margin trajectory and the durability of the bioprocessing rebound: if margins normalize toward the mid-teens and growth holds, the forward methods are right and the premium is earned, and if the recovery stalls, the grounded methods near $30 set a sobering floor.

Catalysts

First-quarter 2026 results, reported in early May, beat and reinforced the recovery narrative. Revenue rose 15 percent year over year to $194 million, with 11 percent organic growth, and adjusted EPS of $0.48 beat the $0.38 consensus by more than 26 percent. GAAP EPS rose 50 percent and adjusted EPS 23 percent. The rebound was led by Process Analytics and Chromatography, with Asia-Pacific surging as China revenue nearly doubled year over year. Repligen reiterated full-year organic revenue growth guidance of 9 to 13 percent and raised adjusted EPS guidance to $1.97 to $2.05.

The strategic moves sharpen the focus on profitability. In March 2026 the company divested its Polymem operations to concentrate on higher-margin core franchises, and it launched a Transformation Office to drive operational efficiency and accelerate margin expansion. A new China OEM partnership extends its reach in a recovering market. On the leadership front, Dr. Martin Madaus became Chair of the Board in March 2026, succeeding the retiring Tony Hunt.

Near-term catalysts to watch: order trends and whether the bioprocessing recovery sustains a mid-teens growth rate, China demand durability, progress on the margin-expansion initiatives from the Transformation Office, and any further portfolio actions. Analyst sentiment is a Buy consensus with a median price target near $180, and several firms have raised targets on the recovery, including UBS to $200, though others remain more cautious.

Peer Cohorts (Per Segment, With Filing Citations)

Repligen (single reportable segment) (reported)

• TECH (BIO-TECHNE Corp)
• FY2025 10-K: …reporting but will have no impact on reported income statement expenses. Other than the items noted above, there have been no new accounting pronouncements not yet effective that we believe have a significant impact, or potential significant impact, on our Consolidated Financial Statements. Note 2 . Revenue…
• FY2025 10-K: ) ​ ( 2 ) ​ ​ ​ ( 19,560 ) ​ ​ ​ ​ ​ ​ ( 19,562 ) Common stock issued for exercise of options 1,083 ​ 10 ​ 24,942 ​ ( 22,163 ) ​ ​ ​ ​ ​ ​ 2,789 Common stock issued for restricted stock awards 63 ​ 1 ​ ( 1 ) ​ ( 6,731 ) ​ ​ ​ ​ ​ ​ ( 6,731 ) Cash dividends ​ ​ ​ ​ ​ ​ ​ ​ ( 50,285 ) ​ ​ ​ ​ ​ ​ ( 50,285 ) Stock-based…
• MRVI (Maravai LifeSciences Holdings, Inc.)
• FY2025 10-K: …collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding, liquidity and financial position of the customer, and the geographic location of the customer. In certain instances, the…
• FY2025 10-K: …of any accruals that the Company believes are appropriate, as well as any related net interest and penalties. Payables to Related Parties Pursuant to the Tax Receivable Agreement The Company is party to a Tax Receivable Agreement ("TRA") with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH 1 and…
• WST (WEST PHARMACEUTICAL SERVICES, INC.)
• FY2025 10-K: …reportable segments. In 2023, one of our customers individually accounted for more than 10% of consolidated net sales, at 10.9 % or $ 322.1 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. The following table presents net sales and long-lived assets, by the…
• FY2025 10-K: …Rule 10b-5 promulgated thereunder in connection with 1) various public statements made by the Company and certain current and former officers regarding its business, operations and prospects and 2) certain current and former officers' transactions in the Company's stock. The action seeks unspecified damages, costs…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.